肿瘤浸润淋巴细胞注射液中多种杂质残留成分的定量分析探索

中国医药导刊 ›› 2023, Vol. 25 ›› Issue (4): 403-409.

肿瘤浸润淋巴细胞注射液中多种杂质残留成分的定量分析探索

王涛1，周足力2，肖蓉心2，初明3，4，王星星5，唐建明5，王铁山6，陈萌7，张秀军5*

1.解放军总医院第五医学中心，北京 100039；
2.北京大学人民医院，北京 100044； 3.北京大学基础医学院，北京 100191； 4.国家卫生健康委员会医学免疫学重点实验室，北京 100191；
5.北京循生免疫医学转化研究院，北京 102600；
6.北京中医药大学，北京 100029； 7.中国标准化研究院，北京 100191

收稿日期:2023-04-10 修回日期:2023-05-20 出版日期:2023-04-28 发布日期:2023-04-28

Quality Control for Expanded Tumor-infiltrating Lymphocytes (TIL)：Quantification of Several Residual Substances

1.The Fifth Medical Center of the PLA General Hospital， Beijing 100039， China；
2.People′s Hospital of Peking University， Beijing 100044， China；
3.School of Basic Medical Sciences， Peking University， Beijing 100191， China；
4.Key Laboratory of Medical Immunology， National Health Commission， Beijing 100191， China；
5.Aeonvital Institute of Clinical and Translational Immunology， Beijing 102600， China；
6.Beijing University of Chinese Medicine， Beijing 100029， China；
7.China National Institute of Standardization， Beijing 100191， China

Received:2023-04-10 Revised:2023-05-20 Online:2023-04-28 Published:2023-04-28

摘要/Abstract

摘要： 目的：旨在建立高效、可靠的实验方法以快速检测肿瘤浸润淋巴细胞（tumor-infiltrating lymphocyte，TIL）产品制备过程中多种细胞培养基辅料的潜在残留。方法：采用酶联免疫吸附法（enzyme-linked immunosorbent assays，ELISA）定量检测TIL产品中的庆大霉素、白介素2（interleukin-2，IL-2）和重组人胰岛素，重点验证检测方法的专属性、准确度、可重现性、精密度、定量限、线性、范围、耐用性等7个指标。结果：商业化ELISA试剂盒不受TIL注射液溶剂和上清液的干扰。使用各自标准品检测上述3种辅料的回收量与实际加标量的差异在30%以内，而且复孔读数的变异系数均<10%。适用线性检测范围分别为0.3~6.0 ng·mL-1、31.3~2000.0 pg·mL-1、3.0~160.0 mIUg·L-1。待测TIL样本中庆大霉素、IL-2和重组人胰岛素残留浓度最高值分别为<0.3 ng·mL-1、37.4 pg·mL-1和<0.1 mIU·L-1，均符合对应的放行标准。结论：现有ELISA试剂盒在检测3种培养基辅料残留时都具有良好的灵敏度、准确性和稳定性，可以快速定量分析TIL产品中是否含有潜在的杂质成分。

关键词: font-size:medium, ">肿瘤浸润淋巴细胞；细胞培养基辅料；杂质残留检测；庆大霉素；白介素2；重组人胰岛素

Abstract: Objective：To establish methods that can efficiently and reliably quantify several residual substances in expanded tumor-infiltrating lymphocytes (TIL) before clinical applications. Methods：Quantitative enzyme-linked immunosorbent assays(ELISA) were used to determine the concentrations of gentamicin， interleukin-2 (IL-2) and recombinant human insulin in TIL products， with a focus on specificity， accuracy， reproducibility， precision， linearity， as well as the limit， range and durability of detection. Results：In testing multiple batches of TIL products， neither TIL suspension buffer nor TIL supernatant interfere with the performance of commercial ELISA kits， and the yields of spiked analytes from test samples closely matched the known amounts (<30% deviations in either direction). The optimal and linear range of detection for gentamicin， IL-2 and recombinant human insulin were 0.3-6.0 ng·mL-1， 31.3-2000.0 pg·mL-1， and 3.0-160.0 mIU·L-1， respectively. The highest concentrations for residual analytes detected in TIL products were <0.3 ng·mL-1， 37.4 pg·mL-1， and <0.1 mIU·L-1， respectively. These parameters all met quality standards for clinical usage. Conclusion：Existing ELISA kits are sensitive， accurate and reliable in measuring three kinds of the above residues in expanded TIL and can serve as rapid tools in quality control procedures.

Key words: font-size:medium, ">Tumor-infiltrating lymphocyte； Supplements to cell culture media； Residue detection； Gentamicin； IL-2； Recombinant human insulin.

中图分类号:

王涛, 周足力, 肖蓉心, 初明, 王星星, 唐建明, 王铁山, 陈萌, 张秀军. 肿瘤浸润淋巴细胞注射液中多种杂质残留成分的定量分析探索[J]. 中国医药导刊, 2023, 25(4): 403-409.

WANG Tao, ZHOU Zuli, XIAO Rongxin, CHU Ming, WANG Xingxing, TANG Jianming, WANG Tieshan, CHEN Meng, ZHANG Xiujun. Quality Control for Expanded Tumor-infiltrating Lymphocytes (TIL)：Quantification of Several Residual Substances[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2023, 25(4): 403-409.

参考文献

[1]Zacharakis N， Chinnasamy H， Black M， et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer [J]. Nat Med， 2018， 24(6)： 724-730.
     [2]Sarnaik AA， Hamid O， Khushalani NI， et al. Lifileucel， a tumor-infiltrating lymphocyte therapy， in metastatic melanoma [J]. J Clin Oncol， 2021， 39(24)： 2656-2666.
     [3]Guo J， Luo N， Ai G， et al. Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen [J]. J Immunother Cancer， 2022， 10(2)：1-10.
     [4]Zacharakis N， Huq LM， Seitter SJ， et al. Breast cancers are immunogenic： immunologic analyses and a phase Ⅱ pilot clinical trial using mutation-reactive autologous lymphocytes [J]. J Clin Oncol， 2022， 40(16)： 1741-1754.
     [5]Karbach J， Kiselicki D， Brand K， et al. Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer [J]. J Immunother Cancer， 2023， 11(1)：1-12.
     [6]Saez-ibanez AR， Upadhaya S， Partridge T， et al. Landscape of cancer cell therapies： trends and real-world data [J]. Nat Rev Drug Discov， 2022， 21(9)： 631-632.
     [7]Rohaan MW， Borch TH， Vandenberg JH， et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma [J]. N Engl J Med， 2022， 387(23)： 2113-2125.
     [8]Tang Y， Zhang AXJ， Chen G， et al. Prognostic and therapeutic tils of cervical cancer-current advances and future perspectives [J]. Mol Ther Oncolytics， 2021， 22： 410-430.
     [9]Tangy F， Moukkadem M， Vindimian E， et al. Mechanism of action of gentamicin components， characteristics of their binding to escherichia coli ribosomes [J]. Eur J Biochem， 1985， 147(2)： 381-386.
     [10]Spolski R， Li P， Leonard WJ. Biology and regulation of IL-2： from molecular mechanisms to human therapy [J]. Nat Rev Immunol， 2018， 18(10)： 648-659.
     [11]Shah P， Forget MA， Frank ML， et al. Combined IL-2， agonistic CD3 and 4-1bb stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes [J]. J Immunother Cancer， 2022， 10(2)：A186.
     [12]Creelan BC， Wang C， Teer JK， et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer： a phase 1 trial [J]. Nat Med， 2021， 27(8)： 1410-1418.
     [13]Wang T， Zhou Z， Chu M， et al. Quantification of tumor cell residue in expanded tumor-infiltrating lymphocytes using flow cytometry and fluorescent EPCAM/Pan-CK-specific antibodies [J]. Chin J Med Guide， 2023， 25(2)： in press.
     [14]Deng F， Yu H， Pan X， et al. Ultra-high performance liquid chromatography tandem mass spectrometry for the determination of five glycopeptide antibiotics in food and biological samples using solid-phase extraction [J]. J Chromatogr A， 2018， 1538： 54-59.
     [15]Wahl O， Jorajuria S. Development and validation of a new uhplc method for related proteins in insulin and insulin analogues as an alternative to the european pharmacopoeia RP-HPLC method [J]. J Pharm Biomed Anal， 2019， 166： 71-82.
     [16]Emami J， Haghighi M， Rostami M， et al. Development and validation of a new robust RP-HPLC method for simultaneous quantitation of insulin and pramlintide in non-invasive and smart glucose-responsive microparticles [J]. Res Pharm Sci， 2022， 17(6)： 594-611.
     [17]Piestansky J， Cizmarova I， Mikus P， et al. An ultra-high-performance liquid chromatography-tandem mass spectrometry method for simultaneous determination of 4 beta-lactam antibiotics， tazobactam， and linezolid in human plasma samples [J]. Ther Drug Monit， 2022， 44(6)： 784-790.
     [18]Cao Y， Smith WC， Bowsher RR. A sensitive chemiluminescent enzyme immunoassay for the bioanalysis of carboxyl-terminal B-chain analogues of human insulin [J]. J Pharm Biomed Anal， 2001， 26(1)： 53-61.
     [19]Qin X， Zheng C， Li Y， et al. Evaluation of the effect of hemolysis on quantitative chemiluminescent immunoassay results for 10 analytes [J]. Clin Lab， 2021， 67(11)：2423-2430.
     [20]Butler JE. Enzyme-linked immunosorbent assay [J]. J Immunoassay， 2000， 21(2-3)： 165-209.
     [21]Boyman O， Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system [J]. Nat Rev Immunol， 2012， 12(3)： 180-190.
     [22]Arenas-ramirez N， Woytschak J， Boyman O. Interleukin-2： biology， design and application [J]. Trends Immunol， 2015， 36(12)： 763-777.
     [23]Mitra S， Leonard WJ. Biology of IL-2 and its therapeutic modulation： mechanisms and strategies [J]. J Leukoc Biol， 2018， 103(4)： 643-655.
     [24]Bao W， Srinivasan SR， Berenson GS. Persistent elevation of plasma insulin levels is associated with increased cardiovascular risk in children and young adults， the bogalusa heart study [J]. Circulation， 1996， 93(1)： 54-59.
     [25]Niswender KD. Basal insulin： physiology， pharmacology， and clinical implications [J]. Postgrad Med， 2011， 123(4)： 17-26.
     [26]Kolb H， Kempf K， Rohling M， et al. Insulin： too much of a good thing is bad [J]. BMC Med， 2020， 18(1)： 224：1-12.

快速检索引用检索图表检索高级检索